恒瑞医药：SHR-1894注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-1894 injection, which is expected to begin soon [1] Group 1: Product Development - SHR-1894 injection is a self-developed therapeutic biological product aimed at treating atopic dermatitis, expected to protect the skin barrier and suppress inflammation [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] - The total research and development investment for the SHR-1894 injection project has reached approximately 40.1 million yuan (unaudited) [1]